Psychedelics such as psilocybin, LSD, MDMA, and ketamine are emerging as promising treatments for depression, PTSD, and substance use disorders. Recent clinical trials and neurobiological studies have highlighted their unique mechanisms, which have opened up a new realm in possible psychiatric treatments. This session will provide attendees with an evidence-based overview of therapeutic potential, safety considerations, and future directions in psychedelic treatments and psychedelic-assisted therapy.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
100% of listed courses are free
14 of 14 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Emergency Medicine
- General & Adult Psychiatry
- Medical Leadership & Administration
- Medical Oncology
- Mood & Anxiety Disorders
- Neurology
- Neuroradiology
- Obstetrics & Gynecology
- Psychopharmacology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Psychiatry
- Radiology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Live
- Credit · Up to 1 credit
-
WhenNov 11, 2025 – Nov 10, 2026
-
Missouri Association of Osteopathic Physicians and Surgeons (MAOPS) Exploring Psilocybin-Assisted Therapy: Emerging Therapeutic Applications, Benefits, & Risks
-
Vindico Medical Education, LLC Psychedelics in Anxiety and Depression: A Practical Update
-
HealthHIV Healing Pathways: Exploring Psychedelics as Emerging Mental Health Tools for People Living with HIV
